Considerations on the Placebo Effect
The discussion about my text on the Mollii Suit at the end of last year was interesting. After the publication of the text, some of my patients approached me and showed me videos of their
Continue reading
Outlook 2024: CAR-T Cell Therapy
I would like to wish all my readers a happy, joyful and above all healthy new year 2024. At the beginning of a year, one is sometimes asked where one sees interesting potentials in terms
Continue reading
Merry Christmas and a Happy New Year
The year 2023 is slowly coming to an end. Therefore, as usual at this point, I would like to wish my readers a blessed Christmas season, as well as luck and health for the coming
Continue reading
Diagnosis Transmission MS – Initial Speech
On the initiative of the Federal Advisory Board for MS Patients (BBMSE), the DMSG recently issued a flyer providing doctors with “tips” for diagnosing multiple sclerosis: recommendations such as “take your time for the patient”
Continue reading
Autologous Hematopoietic Stem Cell Transplantation (aHSCT) – Results from the Swedish MS Registry
In September 2023, a paper from Sweden was published in the Journal of Neurology Neurosurgery and Psychiatry (JNNP) (Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study |
Continue readingExopulse Mollii Suit – not like this …
Recently, the DMSG Federal Association has been receiving an increasing number of inquiries from MS patients regarding the possibility of reimbursement for the Exopulse Mollii Suit by statutory health insurance companies, as well as by
Continue reading
ECTRIMS 2023 in Milan – “We are halfway home, but we are not all the way there”
This year’s annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place from October 12 to 14 in Milan. This most important scientific MS congress discusses the most important
Continue reading
Introduction to Second Opinion
I often have patients who want a second opinion – either on their own initiative or at the suggestion of their treating neurologist or general practitioner. The second opinion is an important and meaningful tool,
Continue reading
MS Medications on the List of “Essential Medicines”
The World Health Organization (WHO) publishes a list of essential medicines every two to three years, which are considered crucial for providing the global population with safe and effective medicines. This “Essential Medicines List (EML)”
Continue reading
Neuronal Stem Cell Therapy for MS
Neural stem cell therapy for MS is still in its infancy. It is being studied for progressive MS and differs from the already known autologous hematopoietic stem cell therapy. This is already used for MS,
Continue reading
